Taysha Gene Therapies Inc (TSHA) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Taysha Gene Therapies Inc (US:TSHA), trading at 5.88. In 2025, Taysha Gene Therapies Inc generated $9.77 Million in revenue and -$93.83 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Taysha Gene Therapies Inc is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: 5.88
- Recent Revenue (2025): $9.77 Million
- Free Cash Flow (2025): -$93.83 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.